Outset Medical (Nasdaq: OM) announced today that the FDA says it addressed all issues cited in a 2023 warning letter.

In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of chronic kidney disease in the US ...

The increasing prevalence of kidney failure and end-stage renal disease, along with a growing incidence of risk factors like diabetes, hypertension, and aging, is driving the demand for artificial ...

Until the FDA warning was published ... sodium citrate anticoagulation while undergoing continuous renal replacement therapy (CRRT) who generally require concomitant continuous infusions of ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Drawing from personal experience, Patty Keating advocates for greater awareness, improved diagnosis, and treatment among ...

Alan Tan, MD, discusses upcoming trials that could change the landscape of frontline and adjuvant renal cell carcinoma ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.

Hemodialysis (HD)-related factors also alter drug clearance. Vigabatrin: in patients with renal impairment the dose should be decreased based on creatinine clearance. The effect of dialysis on ...

Severe CKD requires one of the forms of renal replacement therapy; this may be a form of dialysis, but ideally constitutes a kidney transplant. Science X Daily and the Weekly Email Newsletter are ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.